Garnier L F, Bine-Scheck F, Pruvost P, Wanszelbaum H, Arnaud R
Service de Cardiologie, Centre Hospitalier de Vendôme.
Ann Cardiol Angeiol (Paris). 1992 Sep;41(7):411-7.
Chronic co-administration of digoxin and several antiarrhythmic drugs increases digoxin plasma levels. To determine the effects of the administration of oral cibenzoline on digoxin plasma levels and its effects on clinical and electrocardiographic parameters, we conducted a prospective multicenter study in 22 cardiac patients with a mean age of 66 +/- 12 years (39-85), who were on long term digoxin therapy (0.25 mg once daily for at least 2 weeks) and who required oral cibenzoline therapy in the prevention of recurrence of symptomatic atrial tachyarrhythmias. Cibenzoline was given for 4 weeks at a dose of 130 mg twice daily in patients aged less than 70 years (group I, n = 15) and this dosage was reduced by half in patients over 70 years of age (group II, n = 7). Evaluation of the effects of this combination on clinical and electrocardiographic tolerability as well as the drawing of blood samples for assay of cibenzoline and digoxin took place before and after 4 weeks treatment with cibenzoline. The digoxin plasma levels were (mean +/- sem) 0.96 +/- 0.1 ng.ml-1 before cibenzoline administration and remained unchanged after 4 weeks of combination therapy (1.0 +/- 0.1 ng.ml-1), p > 0.05. Digoxin plasma levels in group I varied from respectively 0.8 +/- 0.1 ng.ml-1 (0.5-1.7) to 0.8 +/- 0.1 ng.ml-1 (0.4-1.5) and in group II from 1.2 +/- 0.2 ng.ml-1 (0.6-2) to 1.4 +/- 0.3 ng.ml-1 (0.7-2.5). This therapy was well tolerated in 16 patients out of 21 evaluable patients (76%) and there was no significant change in vital signs during the study.(ABSTRACT TRUNCATED AT 250 WORDS)
长期联合使用地高辛和几种抗心律失常药物会提高地高辛的血浆水平。为了确定口服西苯唑啉对地高辛血浆水平的影响及其对临床和心电图参数的作用，我们对22名心脏病患者进行了一项前瞻性多中心研究。这些患者平均年龄为66±12岁（39 - 85岁），长期接受地高辛治疗（每日一次0.25毫克，至少持续2周），且需要口服西苯唑啉来预防症状性房性快速性心律失常复发。年龄小于70岁的患者（第一组，n = 15）给予西苯唑啉，剂量为每日两次，每次130毫克，共4周；70岁以上的患者（第二组，n = 7）剂量减半。在西苯唑啉治疗4周前后，评估这种联合用药对临床和心电图耐受性的影响，并采集血样检测西苯唑啉和地高辛。西苯唑啉给药前地高辛血浆水平为（均值±标准误）0.96±0.1纳克/毫升，联合治疗4周后保持不变（1.0±0.1纳克/毫升），p>0.05。第一组地高辛血浆水平分别从0.8±0.1纳克/毫升（0.5 - 1.7）变化至0.8±0.1纳克/毫升（0.4 - 1.5），第二组从1.2±0.2纳克/毫升（0.6 - 2）变化至1.4±0.3纳克/毫升（0.7 - 2.5）。在21名可评估患者中，16名患者（76%）对该治疗耐受性良好，研究期间生命体征无显著变化。（摘要截断于250字）
